Technology | November 14, 2007

Contrast Agent Lowers Side Effects


Guerbet will feature its Oxilan (ioxilan) injection, a contrast agent that is a nonionic low-viscous and low-osmolar monomer at RSNA 2007.
Although opacification is a major metric used to judge the quality of contrast media, other significant characteristics such as ionicity, chemical structure, osmolality and viscosity have important influences on their efficacy and safety. Guerbet has emphasized the point that these additional characteristics can significantly effect visualization, hemodynamics, thrombogenecity, contrast-induced nephropathy and other various clinical outcomes. This emphasis has been implemented in the development of Oxilan, whose chemical characteristics have resulted in high quality imaging with minimal side effects, according to the manufacturer.


Related Content

News | Contrast Media

August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

Home August 17, 2023
Home
News | Contrast Media

July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home July 03, 2023
Home
News | Contrast Media

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Technology | Contrast Media

July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...

Home July 15, 2019
Home
Videos | Contrast Media

Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...

Home June 28, 2019
Home
Feature | Contrast Media | Dave Fornell, Editor

Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...

Home May 31, 2019
Home
News | Contrast Media

May 9, 2019 — Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...

Home May 09, 2019
Home
News | Contrast Media

November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...

Home November 30, 2018
Home
News | Contrast Media

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...

Home September 12, 2018
Home
News | Contrast Media

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...

Home January 19, 2018
Home
Subscribe Now